Is PGEN or IBRX more profitable?

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 484.64% beat ImmunityBio's return on equity. Company Net Margins Return on Equity Return on Assets Precigen -183.98% 484.64% 86.45% ImmunityBio -598.55% N/A -53.33%

Does the media prefer PGEN or IBRX?

In the previous week, Precigen had 16 more articles in the media than ImmunityBio. MarketBeat recorded 34 mentions for Precigen and 18 mentions for ImmunityBio. Precigen's average media sentiment score of 0.73 beat ImmunityBio's score of 0.49 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 5 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PGEN or RYTM?

In the previous week, Precigen had 13 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 34 mentions for Precigen and 21 mentions for Rhythm Pharmaceuticals. Precigen's average media sentiment score of 0.73 beat Rhythm Pharmaceuticals' score of 0.67 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer MIRM or PGEN?

In the previous week, Precigen had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 34 mentions for Precigen and 16 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 0.73 beat Mirum Pharmaceuticals' score of 0.40 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Precigen 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, LNTH or PGEN?

Lantheus has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.27 $233.56M $4.15 24.35 Precigen $9.68M 255.12 -$250.64M -$1.18 N/A

Is LNTH or PGEN more profitable?

Lantheus has a net margin of 18.05% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 484.64% beat Lantheus' return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 18.05% 29.32% 15.00% Precigen -183.98% 484.64% 86.45%

Does the media favor LNTH or PGEN?

In the previous week, Precigen had 7 more articles in the media than Lantheus. MarketBeat recorded 34 mentions for Precigen and 27 mentions for Lantheus. Precigen's average media sentiment score of 0.73 beat Lantheus' score of 0.25 indicating that Precigen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 9 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor COGT or PGEN?

In the previous week, Precigen had 31 more articles in the media than Cogent Biosciences. MarketBeat recorded 34 mentions for Precigen and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.65 beat Precigen's score of 0.73 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Precigen 11 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precigen (PGEN) Competitors

$6.93 +0.04 (+0.54%)

As of 03:50 PM Eastern

Compare

PGEN vs. IBRX, RYTM, MIRM, LNTH, and COGT

Should you buy Precigen stock or one of its competitors? MarketBeat compares Precigen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precigen include ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Cogent Biosciences (COGT).

How does Precigen compare to ImmunityBio?

Precigen (NASDAQ:PGEN) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

33.5% of Precigen shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 41.4% of Precigen shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Precigen currently has a consensus target price of $14.50, suggesting a potential upside of 109.33%. ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 93.86%. Given Precigen's higher probable upside, research analysts plainly believe Precigen is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Precigen has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	255.12	-$250.64M	-$1.18	N/A
ImmunityBio	$165.79M	46.27	-$351.40M	-$0.97	N/A

Precigen has a net margin of -183.98% compared to ImmunityBio's net margin of -598.55%. Precigen's return on equity of 484.64% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	484.64%	86.45%
ImmunityBio	-598.55%	N/A	-53.33%

In the previous week, Precigen had 16 more articles in the media than ImmunityBio. MarketBeat recorded 34 mentions for Precigen and 18 mentions for ImmunityBio. Precigen's average media sentiment score of 0.73 beat ImmunityBio's score of 0.49 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	5 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market.

Summary

Precigen beats ImmunityBio on 11 of the 16 factors compared between the two stocks.

How does Precigen compare to Rhythm Pharmaceuticals?

Precigen (NASDAQ:PGEN) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 484.64% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	484.64%	86.45%
Rhythm Pharmaceuticals	-85.59%	-149.96%	-43.10%

In the previous week, Precigen had 13 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 34 mentions for Precigen and 21 mentions for Rhythm Pharmaceuticals. Precigen's average media sentiment score of 0.73 beat Rhythm Pharmaceuticals' score of 0.67 indicating that Precigen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precigen	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Precigen currently has a consensus price target of $14.50, indicating a potential upside of 109.33%. Rhythm Pharmaceuticals has a consensus price target of $142.38, indicating a potential upside of 28.40%. Given Precigen's higher probable upside, equities analysts clearly believe Precigen is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Rhythm Pharmaceuticals has higher revenue and earnings than Precigen. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precigen	$9.68M	255.12	-$250.64M	-$1.18	N/A
Rhythm Pharmaceuticals	$239.92M	31.67	-$196.54M	-$3.11	N/A

33.5% of Precigen shares are owned by institutional investors. 41.4% of Precigen shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Precigen beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Precigen compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

Mirum Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Precigen. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$569.61M	10.09	-$23.36M	-$13.61	N/A
Precigen	$9.68M	255.12	-$250.64M	-$1.18	N/A

In the previous week, Precigen had 18 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 34 mentions for Precigen and 16 mentions for Mirum Pharmaceuticals. Precigen's average media sentiment score of 0.73 beat Mirum Pharmaceuticals' score of 0.40 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Precigen	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 484.64% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Precigen	-183.98%	484.64%	86.45%

33.5% of Precigen shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 41.4% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Mirum Pharmaceuticals presently has a consensus price target of $137.67, indicating a potential upside of 46.06%. Precigen has a consensus price target of $14.50, indicating a potential upside of 109.33%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Precigen beats Mirum Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Precigen compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Lantheus presently has a consensus price target of $108.11, indicating a potential upside of 7.00%. Precigen has a consensus price target of $14.50, indicating a potential upside of 109.33%. Given Precigen's higher probable upside, analysts plainly believe Precigen is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Lantheus has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.27	$233.56M	$4.15	24.35
Precigen	$9.68M	255.12	-$250.64M	-$1.18	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 1.7% of Lantheus shares are owned by company insiders. Comparatively, 41.4% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Precigen had 7 more articles in the media than Lantheus. MarketBeat recorded 34 mentions for Precigen and 27 mentions for Lantheus. Precigen's average media sentiment score of 0.73 beat Lantheus' score of 0.25 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	9 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 484.64% beat Lantheus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Precigen	-183.98%	484.64%	86.45%

Summary

Lantheus and Precigen tied by winning 8 of the 16 factors compared between the two stocks.

How does Precigen compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Precigen (NASDAQ:PGEN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Precigen has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Precigen	$9.68M	255.12	-$250.64M	-$1.18	N/A

Cogent Biosciences presently has a consensus target price of $45.90, indicating a potential upside of 11.12%. Precigen has a consensus target price of $14.50, indicating a potential upside of 109.33%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Precigen	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cogent Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

In the previous week, Precigen had 31 more articles in the media than Cogent Biosciences. MarketBeat recorded 34 mentions for Precigen and 3 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.65 beat Precigen's score of 0.73 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Precigen	11 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

33.5% of Precigen shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by company insiders. Comparatively, 41.4% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cogent Biosciences has a net margin of 0.00% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 484.64% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Precigen	-183.98%	484.64%	86.45%

Summary

Precigen beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.

Get Precigen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGEN vs. The Competition

Export

Metric	Precigen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.46B	$3.60B	$6.91B	$12.84B
Dividend Yield	N/A	3.77%	2.60%	9.78%
P/E Ratio	-6.64	7.66	281.10	25.44
Price / Sales	255.12	1,199.86	571.60	79.78
Price / Cash	N/A	103.01	71.79	50.79
Price / Book	115.45	16.97	12.85	6.07
Net Income	-$250.64M	-$12.50M	$3.49B	$348.34M
7 Day Performance	16.62%	2.55%	2.48%	3.07%
1 Month Performance	23.70%	-4.87%	-2.81%	-3.04%
1 Year Performance	278.52%	52.93%	75.60%	20.78%

Precigen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGEN Precigen	3.4928 of 5 stars	$6.93 +0.5%	$14.50 +109.3%	+257.0%	$2.46B	$9.68M	N/A	190	Trending News Earnings Report Analyst Forecast Insider Trade Options Volume Analyst Revision
IBRX ImmunityBio	2.4052 of 5 stars	$6.99 -1.5%	$14.20 +103.1%	+200.8%	$7.44B	$113.29M	N/A	590	Trending News Earnings Report Analyst Revision
RYTM Rhythm Pharmaceuticals	3.1808 of 5 stars	$106.13 +3.9%	$138.73 +30.7%	+25.0%	$7.00B	$189.76M	N/A	140	News Coverage Positive News Earnings Report Analyst Forecast
MIRM Mirum Pharmaceuticals	3.0284 of 5 stars	$114.20 +1.0%	$143.40 +25.6%	+104.1%	$6.89B	$521.31M	N/A	140	Trending News Earnings Report Analyst Forecast Insider Trade Gap Down
LNTH Lantheus	2.845 of 5 stars	$108.03 +3.1%	$110.43 +2.2%	+39.7%	$6.82B	$1.54B	26.03	1,193	Earnings Report Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGEN) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precigen (PGEN) Competitors

PGEN vs. IBRX, RYTM, MIRM, LNTH, and COGT

How does Precigen compare to ImmunityBio?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Summary

How does Precigen compare to Lantheus?

Summary

How does Precigen compare to Cogent Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precigen (PGEN) Competitors

PGEN vs. IBRX, RYTM, MIRM, LNTH, and COGT

How does Precigen compare to ImmunityBio?

Do insiders & institutionals hold more shares of PGEN or IBRX?

Do analysts recommend PGEN or IBRX?

Which has better valuation & earnings, PGEN or IBRX?

Is PGEN or IBRX more profitable?

Does the media prefer PGEN or IBRX?

Which has more volatility & risk, PGEN or IBRX?

Summary

How does Precigen compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, PGEN or RYTM?

Is PGEN or RYTM more profitable?

Does the media refer more to PGEN or RYTM?

Do analysts prefer PGEN or RYTM?

Which has better valuation and earnings, PGEN or RYTM?

Do insiders & institutionals believe in PGEN or RYTM?

Summary

How does Precigen compare to Mirum Pharmaceuticals?

Which has more risk & volatility, MIRM or PGEN?

Which has stronger earnings & valuation, MIRM or PGEN?

Does the media prefer MIRM or PGEN?

Is MIRM or PGEN more profitable?

Do institutionals & insiders have more ownership in MIRM or PGEN?

Do analysts recommend MIRM or PGEN?

Summary

How does Precigen compare to Lantheus?

Do analysts prefer LNTH or PGEN?

Which has stronger valuation & earnings, LNTH or PGEN?

Do institutionals and insiders have more ownership in LNTH or PGEN?

Does the media favor LNTH or PGEN?

Which has more risk and volatility, LNTH or PGEN?

Is LNTH or PGEN more profitable?

Summary

How does Precigen compare to Cogent Biosciences?

Which has higher earnings & valuation, COGT or PGEN?

Do analysts recommend COGT or PGEN?

Which has more volatility and risk, COGT or PGEN?

Does the media favor COGT or PGEN?

Do insiders & institutionals have more ownership in COGT or PGEN?

Is COGT or PGEN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN vs. The Competition

Precigen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools